Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia

ClinicalTrials.gov ID: NCT01912560

Public ClinicalTrials.gov record NCT01912560. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 11:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine the safety and efficacy of different doses of CAT-2003 in patients with hyperlipidemia when CAT-2003 is taken for 4 weeks. The study will evaluate effects of CAT-2003 on (1) fasting triglycerides and non-HDL-C in patients with moderate hypertriglyceridemia and (2) fasting LDL-C levels in combination with a statin in patients with hypercholesterolemia who are on a statin.

Study identification

NCT ID
NCT01912560
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Catabasis Pharmaceuticals
Industry
Enrollment
99 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 69 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2013
Primary completion
Nov 30, 2013
Completion
Nov 30, 2013
Last update posted
Jul 27, 2016

2013

United States locations

U.S. sites
13
U.S. states
8
U.S. cities
10
Facility City State ZIP Site status
Not listed Muscle Shoals Alabama 35662
Not listed Los Angeles California 90057
Not listed Jacksonville Florida 32223
Not listed Miami Florida 33143
Not listed Winter Park Florida 32792
Not listed Kansas City Kansas 66160
Not listed Louisville Kentucky 40213
Not listed Auburn Maine 04120
Not listed Raleigh North Carolina 27609
Not listed Raleigh North Carolina 27612
Not listed Cincinnati Ohio 45219
Not listed Cincinnati Ohio 45227
Not listed Cincinnati Ohio 45246

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

Recently updated Dyslipidemia trials

Other public records listing Dyslipidemia. Sorted by last update posted; newest first. Not a recommendation.

All Dyslipidemia trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01912560, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 27, 2016 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01912560 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →